New-onset Refractory Status Epilepticus after BNT162b2 mRNA COVID-19 Vaccination
Journal of the Korean Neurological Association
;
: 204-209, 2023.
Article
in Korean
| WPRIM
| ID: wpr-1001731
ABSTRACT
Increasing importance of vaccination during coronavirus disease 2019 (COVID-19) pandemic, several vaccines were developed. Messenger RNA (mRNA) vaccines including BNT162b2 (Pfizer, New York, NY, USA; BioNTech, Mainz, Germany), mRNA-1273 (Moderna, Cambridge, MA, USA) have been disclosed side effects such as thrombocytopenia, myocarditis and headache in general. In addition, adverse effects due to autoimmune responses induced by spike glycoproteins of mRNA vaccines are rarely reported such as the Guillain-Barre syndrome, autoimmune encephalitis and so on. Herein, we report a rare case of encephalitis with new-onset refractory status epilepticus after BNT162b2 mRNA COVID-19 vaccination improved with immune therapy.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Korean
Journal:
Journal of the Korean Neurological Association
Year:
2023
Type:
Article
Similar
MEDLINE
...
LILACS
LIS